Article info

Download PDFPDF

Original research
Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks 26–52, including a treatment switch from reference ADL to PF-06410293

Authors

  1. Correspondence to Dr Roy M Fleischmann; rfleischmann{at}arthdocs.com
View Full Text

Citation

Fleischmann RM, Alvarez DF, Bock AE, et al
Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks 26–52, including a treatment switch from reference ADL to PF-06410293

Publication history

  • Received January 11, 2021
  • Revision received March 22, 2021
  • Accepted March 25, 2021
  • First published April 21, 2021.
Online issue publication 
April 21, 2021
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.